Mersana Therapeutics 的收益和收入未达到预期，但其股价在大量交易中上涨。 Mersana Therapeutics missed earnings and revenue estimates but saw its stock rise on heavy trading.

梅萨纳治疗机构报告说,第三季度损失为每股1.51美元,损失估计数7美元,收入1 101万美元,低于预期的1 420万美元。 Mersana Therapeutics reported a third-quarter loss of $1.51 per share, missing estimates by $0.07, and revenue of $11.01 million, below the $14.20 million expected. 尽管成交量不佳，但该股仍因成交量大而上涨 0.49 美元至 27.92 美元。 Despite the miss, the stock rose $0.49 to $27.92 on heavy volume. 临床阶段生物制药公司与Janssen、Merck KGaA和其他公司建立了伙伴关系,开发抗体抗体药物疗法以治疗癌症。 The clinical-stage biopharma company, developing antibody-drug conjugates for cancer, has partnerships with Janssen, Merck KGaA, and others. 分析师保持"持有"评级的共识,平均价格目标为55.55美元,机构所有权为93.92%. Analysts maintain a consensus "Hold" rating with a $55.55 average price target, and institutional ownership is 93.92%.